This is a well written protocol and accompanying manuscript. While there are no major problems with the protocol design, there is one element of concern that should be addressed by the investigators. 1) In the description of secondary outcome measures on page 13, the investigators describe two clinical scenarios: a) Patients who develop congestive cardiac failure (defined earlier as "heart failure will be diagnosed by the onset of symptoms of orthopnoea with or without peripheral oedema and objective signs of heart failureraised jugular venous pressure, third heart sound or gallop rhythm, pulmonary plethora on chest X-ray or similar -all in the context of known advanced LV dysfunction (ie echocardiogram LVEF < 25%") will be withdrawn from intervention, will be invited to continue to be followed up (as per protocol) and therapy thereafter will be at the discretion of clinician managing the patient; and b) Participants who show a progressive reduction in LVEF% on at least two assessments at least three months apart, culminating in LVEF < 35%, will be deemed to have reached a predefined study end point, mandating the introduction of active therapy. In both cases, it seems like the described patient could be in the placebo arm. This is very different from the standard of care and should be clarified by the investigators. In case a, could the investigators have monitored a subject in clinical heart failure in a blinded fashion with the patient possibly taking placebo? Same for case b? What is the justification in case b for waiting until the EF reaches <35%. That is too late to wait to begin optimal therapy, especially if there is a risk of placebo use. Could the investigators please clarify these scenarios and if they more proactively addressed subjects who developed decreased systolic function (much less symptomatic heart failure) during the trial.
There are some aspects of the protocol which could be addressed more clearly in the manuscript. 1) It is not entirely clear how the investigators plan to answer all the questions regarding preventive therapy that are presented in the manuscript. 1) Age: the authors include a wide range of ages (5-13) and a small likelihood of many of these patients developing systolic dysfunction during this period, treated or untreated. The authors state from previous literature that up to 20-30% of children can develop systolic dysfunction by age 10 yo. Did they include this estimation in their trial powering, or is it just based on a 5% change in LVEF measure over time? Is a change of 5% within the normal range (Subject 1 drops 65% to 60%) equally important as a change to the abnormal cardiomyopathy range (subject 2 drops 56% to 51% )? It is difficult to say, especially if that subject stays at 60% for the next few echos. In the analysis, will Subject 1's age at 65-60% be considered as important as Subject 2's age at 56-51%? 2) Type of therapy: the trial examines only one type of combination therapy, perindopril and bisoprolol. Yet the investigators write about all the other possible combinations that have not been studied, including monotherapy with ACEi or BB or mineralocorticoid receptor antagonist (MRA). Why did the investigators choose this combination therapy over the others? And why not monotherapy? If benefits are seen, the next question is perhaps whether ACEi or BB alone is as effective. So the trial will answer the question regarding combination therapy and age when LVEF drops 5%, but not sure how much the result can be expanded beyond that and the manuscript should reflect these limitations.
2) The investigators should justify why they chose to determine LVEF by the wall motion score index. Is there literature to support its use in DMD? Two recent articles have shown that EF determined by 2D echo is the most limited assessment of systolic function in DMD subjects. Shortening fraction by M-mode is a better 2D measure and cardiac MR (CMR) is perhaps the best.
3) For obvious reasons, echo is the most appropriate modality for testing every 6 months. Myocardial strain imaging is an excellent measure that could provide important information on myocardial changes over time, even without a 5% drop in EF. The investigators mention tissue Doppler imaging. So along with tissue velocities, will they also measure myocardial strain? It is listed in appendix (not included), but not noted in manuscript. This should be more clearly stated in the secondary outcomes. If not, they should explain why they are not using this outcome measure, but it is a real weakness of the protocol if this in not included. 4) Regarding the CMR, it seems like a missed opportunity to obtain a CMR at the end of the study and not at the beginning. The authors should explain why this decision was made and any limitations they factored into this decision. CMR in DMD is becoming the best modality for cardiac assessment, especially from a research standpoint. CMR is better at determining LV systolic function, myocardial strain and provides assessment of myocardial "fibrosis". If a baseline CMR had been included, this would have provided excellent pre-and post-therapy measures.
5) There is an appendix for biomarkers. The appendix is not included so it is not clear what biomarkers are studied. This could be an important outcome measure and should be discussed in the manuscript. Both imaging and serum biomarkers will be very important outcomes in cardiac clinical trials in DMD and it would important to know the focus of this trial.
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GENERAL COMMENTS
This is an important trial with relevance in the management of boys with DMD. The investigators should be congratulated for undertaking such as study.
A couple of points to consider: 1. The authors acknowledge that a 2 x 2 factorial study design may have been better, but had concerns about the viability of such an approach. I agree that a 2 x 2 study would have been preferable. 2. Is placebo the correct comparator given that there is evidence for the use of ACEi in this patient group (and 1 of 2 references in this area is included). Current accepted practice would be ACEi, for which there is evidence of improved outcome, as preventive treatment in those with normal LVEF, with BB added when LV dysfunction develops. 3. The use of a combination capsule is important in an attempt to reduce pill burden and may be even more important in more advanced disease, when swallowing can become an issue. 4. Sample size calculations have used appropriate values for variability of LVEF measurement, which is important given that the primary end-point is a difference of only 5% in LVEF and this measure by echo has quite wide variability.
VERSION 1 -AUTHOR RESPONSE
Response to reviewer 1 comments: 1a. Secondary outcome measures -justification for allowing LVEF% to fall to < 35% or onset of heart failure This study had a very long gestation and was originally conceived at a time when cardiac medications were not prescribed in patients with DMD ahead of the onset of heart failure in most hospitals. In discussion with funders, it was agreed that -for the results to change the rather nihilistic practice of the time in favour of earlier or prophylactic heart therapy, the primary end-points needed to be sufficient robust to convince non-specialists. This meant allowing greater differences to emerge before breaking randomization and mandating active therapy. This was also to avoid patients being withdrawn from the study on the basis of minor or temporary deteriorations in left ventricular function compared to previous assessments. However, given the age range of participants -all of whom had to have normal heart function at study entry, it was not expected that any would develop overt heart failure within even the maximum 5-year duration of follow-up. Nor was it anticipated that LVEF would fall to below 35%. These end-points were specified, therefore, more to deter investigators from withdrawing patients unnecessarily based on minor deteriorations in LV-measures than that patients, whose cardiomyopathy was progressing rapidly, would be denied active therapy. Furthermore, since some deteriorations were to be expected among participants in either arm of the study during longer follow-up, over-sensitive criteria mandating active therapy were likely to jeopardize the aim of showing clinically relevant differences between active therapy and placebo, in our view, at the time the study was planned. Clarification of protocol aspects: 1b. Wide age range In recognition of the fact that heart evaluations aim to detect functional abnormalities, which only become apparent after significant myocyte loss has occurred and that -to be effective, therapy needs to be started as early as tolerable and safe, this trial aimed to assess tolerability / safety as well as efficacy of the medicines studied. The optimum age to start prophylactic heart therapy is unknown but we thought it possible that options for prophylaxis with combined ACE-inhibitor and beta-blocker therapy might be limited by intolerance -particularly in younger children. Initially we opted to only include children aged seven years and above but later dropped eligibility to age five years to assess tolerability of the combination further and also to bolster recruitment. The lower likelihood of developing detectable cardiac dysfunction in participants at the younger end of the spectrum was not factored into the study's power calculation. However, several pre-specified subgroup analyses were planned to take account of this. 1c. Interpretation of changes in LVEF% within the normal range The limitations of LVEF% are well known. It is not independent of the heart's pre-or after-loading conditions and so can vary day-to-day or during intercurrent illnesses. By measuring LVEF% six monthly over a minimum of 36 months, it was anticipated that such fluctuations could be distinguished from progressive pathological deteriorations. We agree with reviewer comment that it would be inappropriate to interpret variations of LVEF% within the 'normal range' as having clinical significance. However, divergence in the trajectory of serial group EF% measures over the course of participation would indicate a therapy effect compared to placebo, whereas if therapy were ineffective variations would be expected to balance out between study arms. To allow for these various possibilities, actual LVEF% at 36 months and, if sufficient data, at 60 months will also be compared as will fractional shortening and 'head count' of patients in each arm meeting pre-defined definitions for cardiomyopathy. 1d. Only one type of therapy combination being tested?
In designing the protocol, we considered firstly whether a placebo arm was ethically justified and came to the conclusion that it was -based on all available evidence at the time. Ideally we would have liked to conduct a four arm study (perindopril alone, bisoprolol alone, perindopril and bisoprolol, placebo) but rapidly realised that there were insufficient potential recruits available to the centres involved to undertake this. Furthermore the cost of a more complex study over such a long time period was considered prohibitive. Despite the fact that the evidence of efficacy for prophylactic perindopril in DMD is weak and disputed, we considered that combining it with bisoprolol should increase efficacy and would add new information to what had previously been studied by Duboc et al (2005) . Beta-blocker therapy is established as an important part of cardiomyopathy therapy and we had already observed that sinus tachycardia often heralds or is present when early ventricular dysfunction becomes detectable in patients with DMD. We reasoned also that, if normal day-to-day cardiac contraction causes abnormal myocte loss and need for repair in DMD, slowing heart rate and reducing the force of left ventricular contraction by beta-blockade, might be expected to mitigate the process. In various discussions at the planning stage of the protocol, it was the view of most experts that, in the management of DMD more-generally, combination therapy is more likely to be needed to really modify the course of the condition -hence steroid and ACE-inhibitors, ACE-inhibitors and eplerenone, etc. In summary on this point, we considered combination therapy a more useful regime to test than a single agent and that the results of a study of combination therapy would be more clinically-instructive -regardless of the findings. 2. Choice of wall motion score derived LVEF% In our experience of using echo-imaging in paediatric and adult patients with DMD, all measures can be obtained readily initially but many become increasingly difficult as patients become wheel-chair dependent, rib-spaces reduce the 'echo-window' and obesity develops from prolonged steroid use. Even our experienced paediatric echo-cardiographers were not consistently able to obtain LVEFmeasures using Simpson's method in older children with DMD while we were always able to derive it from wall motion scoring. Based on this previous experience we opted to use LVEF% derived from wall motion scoring instead of the probably more accurate measure by the Simpson's method. 3. Use of myocardial strain Tissue Doppler imaging is being used to complement and provide a more sensitive measure of subtle left ventricular dysfunction than LVEF% or FS% in the protocol. We did consider using speckled tracking measures also but found, in our initial assessment, that it could only be obtained in about half of the DMD subjects in which we tried it. It was for this reason alone that this measure was not included in the protocol. 4. cMRI at study end but not at study entry? We decided after extensive consideration to use echo-assessments instead of cMRI for the following reasons: (i) young children might not tolerate the length and nature of cMRI evaluations without sedation or general anaesthesia. This was considered unreasonable in a research study planned in 2009; (ii) at the older end of the study end age, steroid induced body mass or contractures in some DMD patients makes them unable to fit into the confined scanner space or tolerate their repeat scan. We feared that in combination with (i), this could result in significant loss of interpretable data for entry versus exit comparisons -undermining the study power; (iii) Older DMD patients do not to tolerate lying supine for long due to respiratory muscle weakness without ventilation support. This explains why breathing motion artefact not uncommonly reduces cMRI scan quality. Although the use of noninvasive BIPAP support during cMRI imaging can partly overcome this, deploying it increases the complexity and length of the scanning process; (iv) finally, at the time the study was planned began in 2005, cMRI imaging of the heart was not well established at some of the hospitals interested in taking part. It was after considering this combination of potential problems that we decided not to use cMRI as the primary modality of evaluation for the study. However, we decided to add cMRI at study exit in a later version of the protocol specifically to provide an assessment of the extent of fibrosis in participants who had completed at least 36 month of trial medications.
Biomarker assessments
The appendix to the protocol on biomarker testing is now included in the study protocol.
Response to reviewer 2 comments: 1. '2 x 2 factorial design better for the study' We agree that this would have been a preferable protocol but for the reasons explained in '1d' above the size and cost of running such a study and the limited number of potential participants made this design impractical and so unlikely to be able to secure funding. In the end we concluded that a study with longer follow up rather than a shorter duration with more therapy arms was more clinically relevant in patients with DMD. 2. 'Is placebo the correct comparator …' This is a critical point to understanding the main rationale for the study. Although almost all accept that standard therapy for left ventricular systolic dysfunction (ie: ACE-inhibitor, beta-blocker, mineralocorticoid receptor blocker) is beneficial -once left ventricular dysfunction becomes detectable, the evidence in patients with DMD comes almost exclusively from cohort series with no placebo comparator. This evidence, therefore, is scientifically weak but has been adopted generally in the absence of more robust data and in recognition of the reality that the benefits of therapy will never be tested in a RCT in DMD. The evidence to support the use of some or all of these same medications prophylactically is even more deficient and, in our opinion, scientifically inconclusive. The results of the study by Duboc et al (2005) showed that fewer patients had detectable cardiomyopathy after 60 months of perindopril therapy as compared to those randomised to placebo, but there was no difference in group-mean measures of left ventricular function at either 36 or 60 months overall. The more recent study by Rahman et al (2015) of eplerenone in patients already taking other cardio-active therapies included some who already had reduced ejection fraction. So it was not really a test of the value of a prophylactic intervention. When this study was originally being planned, only the French study results were available and the clinical significance of the findings was debated. In our opinion, another placebo controlled trial was both necessary and ethically justifiable. We were also conscious of the fact that the opportunity to conduct a placebo controlled study ethically was shrinking and that, having further placebo data from this study, would help interpretation of the results of subsequent studies in which a placebo arm could not be justified.
3. 'Use of a combination capsule …' A combination capsule was used for the study -mainly to ensure double-blinding from the point of manufacture and so reduce the effects of bias from any quarter throughout. The resulting capsule was larger than the original tablets, of course, and so an criterion for study entry was that boys needed to be able to swallow an unfilled dummy capsule at the initial visit. 4. Sample-size for the study A 5% difference in left ventricular ejection fraction between active and placebo treated participants was considered the minimum basis on which to formulate guidance for the routine prophylactic management of cardiac involvement in children with DMD. 
GENERAL COMMENTS
The authors answered the comments appropriately. Within their answer, they acknowledge a significant number of limitations related to the time of study design and outcome design. In order for the manuscript to be appropriate for publication, there should be a more extensive discussion of the limitations of the study. This should the decisions for study design that is presented in the response to comments. They should also include limitations regarding who the study design would not be replicated in today's DMD cardiomyopathy climate. With an acknowledgement of these limitations, the manuscript should be accepted. 
REVIEWER

GENERAL COMMENTS
The revision has improved the manuscript
